{"protocolSection": {"identificationModule": {"nctId": "NCT00789191", "orgStudyIdInfo": {"id": "NN304-3511"}, "secondaryIdInfos": [{"id": "2008-001050-40", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Novo Nordisk A/S", "class": "INDUSTRY"}, "briefTitle": "Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes", "officialTitle": "Effect of Detemir and Sitagliptin on Blood Glucose Control in Subjects With Type 2 Diabetes Mellitus"}, "statusModule": {"statusVerifiedDate": "2017-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-11"}, "primaryCompletionDateStruct": {"date": "2009-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-11-10", "studyFirstSubmitQcDate": "2008-11-10", "studyFirstPostDateStruct": {"date": "2008-11-11", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-11-18", "resultsFirstSubmitQcDate": "2010-11-18", "resultsFirstPostDateStruct": {"date": "2010-12-10", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-02-02", "lastUpdatePostDateStruct": {"date": "2017-03-14", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novo Nordisk A/S", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This trial is conducted in Asia, Europe and North America. This trial aims for comparison of the effect on the glycemic control in subjects with type 2 diabetes of basal insulin analogue with one oral anti-diabetic drug (OAD) versus oral anti-diabetic drug alone."}, "conditionsModule": {"conditions": ["Diabetes", "Diabetes Mellitus, Type 2"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 222, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Comb", "type": "EXPERIMENTAL", "description": "Combination therapy of insulin detemir once daily plus sitagliptin added to subject's own pre-trial metformin treatment", "interventionNames": ["Drug: insulin detemir", "Drug: sitagliptin", "Drug: metformin"]}, {"label": "Sita", "type": "ACTIVE_COMPARATOR", "description": "Monotherapy of sitagliptin once daily added to subject's own pre-trial metformin and/or sulphonylurea (SU) treatment", "interventionNames": ["Drug: sitagliptin", "Drug: metformin", "Drug: sulphonylurea"]}], "interventions": [{"type": "DRUG", "name": "insulin detemir", "description": "The detemir insulin dose is injected subcutaneously (under the skin) once daily in the evening and will be titrated (individually adjusted) weekly throughout the trial.", "armGroupLabels": ["Comb"]}, {"type": "DRUG", "name": "sitagliptin", "description": "The sitagliptin dose is 100 mg/ day and should be kept stable throughout the trial. Frequency of sitagliptin is once daily.", "armGroupLabels": ["Comb", "Sita"]}, {"type": "DRUG", "name": "metformin", "description": "Metformin treatment with at least 1000 mg/ day. Dose and dosing frequency should remain unchanged throughout the trial.", "armGroupLabels": ["Comb", "Sita"]}, {"type": "DRUG", "name": "sulphonylurea", "description": "Sulphonylurea (SU) dose and dosing frequency should initially remain unchanged. In case of hypoglycaemia SU dose may be reduced at the discretion of the investigator.", "armGroupLabels": ["Sita"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "HbA1c (Glycosylated Haemoglobin A1c)", "timeFrame": "Week 26"}], "secondaryOutcomes": [{"measure": "Number of Subjects Achieving HbA1c Less Than or Equal to 7.0%", "timeFrame": "Week 26"}, {"measure": "Number of Subjects Achieving HbA1c Less Than or Equal to 7.0% Without Symptomatic Hypoglycaemia", "description": "Symptomatic hypoglycaemia is biochemically confirmed hypoglycaemia or major hypoglycaemia", "timeFrame": "Week 26"}, {"measure": "Number of Subjects Achieving HbA1c Less Than or Equal to 6.5%", "timeFrame": "Week 26"}, {"measure": "Number of Subjects Achieving HbA1c Less Than or Equal to 6.5% Without Symptomatic Hypoglycaemia", "description": "Symptomatic hypoglycaemia is biochemically confirmed hypoglycaemia or major hypoglycaemia", "timeFrame": "Week 26"}, {"measure": "Change in BMI (Body Mass Index)", "timeFrame": "Week 0, Week 26"}, {"measure": "Change in Body Weight", "timeFrame": "Week 0, Week 26"}, {"measure": "FPG (Fasting Plasma Glucose)", "timeFrame": "Week 26"}, {"measure": "Hypoglycemic Episodes", "description": "Overall: All episodes. Minor: Symptomatic, with PG \\< 3.1 mmol/L. Symptoms only: Symptomatic with PG \u2265 3.1 mmol/L", "timeFrame": "Weeks 0-26"}, {"measure": "Hypoglycemic Episodes: Day Time", "description": "Day time: Episodes between 6 pm and 11 am. Overall: All episodes. Minor: Symptomatic, with PG \\< 3.1 mmol/L. Symptoms only: Symptomatic with PG \u2265 3.1 mmol/L", "timeFrame": "Weeks 0-26"}, {"measure": "Hypoglycemic Episodes: Night Time", "description": "Night time: Episodes between 11 am and 6 pm. Overall: All episodes. Minor: Symptomatic, with PG \\< 3.1 mmol/L. Symptoms only: Symptomatic with PG \u2265 3.1 mmol/L", "timeFrame": "Weeks 0-26"}, {"measure": "Self-measured 9-point Plasma Glucose Profile", "timeFrame": "Week 26"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosed with type 2 diabetes for at least 6 months before trial start\n* Treatment with at least 1000 mg metformin per day for at least 3 months\n* Insulin-naive (short-term insulin treatment of up to 14 days is allowed)\n* DPP-4 (dipeptidyl peptidase-4) inhibitor naive\n* HbA1c (glycosylated haemoglobin A1c) between 7.5-10.0% by central laboratory analysis\n* BMI (Body Mass Index) lesser than or equal to 45.0 kg/m2\n* Able and willing to take one subcutaneous injection every day\n* Able and willing to perform mandatory SMPG (self measured plasma glucose) measurements\n\nExclusion Criteria:\n\n* Known or suspected allergy or intolerance to any of the trial products or related products\n* Severe hypertension\n* Treatment with thiazolidinedione (TZD) or GLP-1 (glucagon-like peptide-1) analogues within 2 months prior to trial start\n* Cardiac disease, within the last 12 months\n* Impaired hepatic function\n* Impaired renal function\n* Proliferative retinopathy or macular oedema requiring acute treatment\n* Female of childbearing potential\n* Known or suspected abuse of alcohol, narcotics or illicit substances", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Global Clinical Registry (GCR, 1452)", "affiliation": "Novo Nordisk A/S", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novo Nordisk Investigational Site", "city": "Vestavia", "state": "Alabama", "zip": "35209", "country": "United States", "geoPoint": {"lat": 33.44872, "lon": -86.78777}}, {"facility": "Novo Nordisk Investigational Site", "city": "Orange", "state": "California", "zip": "92869", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -117.85311}}, {"facility": "Novo Nordisk Investigational Site", "city": "Santa Monica", "state": "California", "zip": "90404", "country": "United States", "geoPoint": {"lat": 34.01945, "lon": -118.49119}}, {"facility": "Novo Nordisk Investigational Site", "city": "Dunwoody", "state": "Georgia", "zip": "30338", "country": "United States", "geoPoint": {"lat": 33.94621, "lon": -84.33465}}, {"facility": "Novo Nordisk Investigational Site", "city": "West Seneca", "state": "New York", "zip": "14224", "country": "United States", "geoPoint": {"lat": 42.85006, "lon": -78.79975}}, {"facility": "Novo Nordisk Investigational Site", "city": "Cincinnati", "state": "Ohio", "zip": "45245", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Novo Nordisk Investigational Site", "city": "Dayton", "state": "Ohio", "zip": "45439", "country": "United States", "geoPoint": {"lat": 39.75895, "lon": -84.19161}}, {"facility": "Novo Nordisk Investigational Site", "city": "Norristown", "state": "Pennsylvania", "zip": "19401", "country": "United States", "geoPoint": {"lat": 40.1215, "lon": -75.3399}}, {"facility": "Novo Nordisk Investigational Site", "city": "Chattanooga", "state": "Tennessee", "zip": "37411", "country": "United States", "geoPoint": {"lat": 35.04563, "lon": -85.30968}}, {"facility": "Novo Nordisk Investigational Site", "city": "Dallas", "state": "Texas", "zip": "75246", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Novo Nordisk Investigational Site", "city": "Coquitlam", "state": "British Columbia", "zip": "V3K 3P4", "country": "Canada", "geoPoint": {"lat": 49.28297, "lon": -122.75262}}, {"facility": "Novo Nordisk Investigational Site", "city": "New Westminster", "state": "British Columbia", "zip": "V3L 3W5", "country": "Canada", "geoPoint": {"lat": 49.20678, "lon": -122.91092}}, {"facility": "Novo Nordisk Investigational Site", "city": "St. John's", "state": "Newfoundland and Labrador", "zip": "A1A 3R5", "country": "Canada", "geoPoint": {"lat": 47.56494, "lon": -52.70931}}, {"facility": "Novo Nordisk Investigational Site", "city": "Cambridge", "state": "Ontario", "zip": "N1R 7L6", "country": "Canada", "geoPoint": {"lat": 43.3601, "lon": -80.31269}}, {"facility": "Novo Nordisk Investigational Site", "city": "Niagara Falls", "state": "Ontario", "zip": "L2E 7H1", "country": "Canada", "geoPoint": {"lat": 43.10012, "lon": -79.06627}}, {"facility": "Novo Nordisk Investigational Site", "city": "Toronto", "state": "Ontario", "zip": "M3J 1N2", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"facility": "Novo Nordisk Investigational Site", "city": "Toronto", "state": "Ontario", "zip": "M9W 4L6", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"facility": "Novo Nordisk Investigational Site", "city": "Sherbrooke", "state": "Quebec", "zip": "J1H 4J6", "country": "Canada", "geoPoint": {"lat": 45.40008, "lon": -71.89908}}, {"facility": "Novo Nordisk Investigational Site", "city": "St. Romuald", "state": "Quebec", "zip": "G6W 5M6", "country": "Canada", "geoPoint": {"lat": 46.75818, "lon": -71.23921}}, {"facility": "Novo Nordisk Investigational Site", "city": "Niagara Falls", "zip": "L2G 5X7", "country": "Canada", "geoPoint": {"lat": 43.10012, "lon": -79.06627}}, {"facility": "Novo Nordisk Investigational Site", "city": "Helsinki", "zip": "FI-00350", "country": "Finland", "geoPoint": {"lat": 60.16952, "lon": 24.93545}}, {"facility": "Novo Nordisk Investigational Site", "city": "Loimaa", "zip": "FI-32200", "country": "Finland", "geoPoint": {"lat": 60.84972, "lon": 23.0561}}, {"facility": "Novo Nordisk Investigational Site", "city": "Oulu", "zip": "FI-90220", "country": "Finland", "geoPoint": {"lat": 65.01236, "lon": 25.46816}}, {"facility": "Novo Nordisk Investigational Site", "city": "Pieks\u00e4m\u00e4ki", "zip": "76100", "country": "Finland", "geoPoint": {"lat": 62.3, "lon": 27.13333}}, {"facility": "Novo Nordisk Investigational Site", "city": "Pori", "zip": "FI-28100", "country": "Finland", "geoPoint": {"lat": 61.48333, "lon": 21.78333}}, {"facility": "Novo Nordisk Investigational Site", "city": "Sein\u00e4joki", "zip": "FI-60100", "country": "Finland", "geoPoint": {"lat": 62.79446, "lon": 22.82822}}, {"facility": "Novo Nordisk Investigational Site", "city": "Brest", "zip": "29200", "country": "France", "geoPoint": {"lat": 48.3903, "lon": -4.48628}}, {"facility": "Novo Nordisk Investigational Site", "city": "LA ROCHE-sur-YON cedex 9", "zip": "85295", "country": "France", "geoPoint": {"lat": 46.66667, "lon": -1.43333}}, {"facility": "Novo Nordisk Investigational Site", "city": "Le Creusot", "zip": "71200", "country": "France", "geoPoint": {"lat": 46.80714, "lon": 4.41632}}, {"facility": "Novo Nordisk Investigational Site", "city": "Lille", "zip": "59037", "country": "France", "geoPoint": {"lat": 50.63297, "lon": 3.05858}}, {"facility": "Novo Nordisk Investigational Site", "city": "Montigny-les-Metz", "zip": "57950", "country": "France", "geoPoint": {"lat": 49.09435, "lon": 6.15167}}, {"facility": "Novo Nordisk Investigational Site", "city": "Narbonne", "zip": "11108", "country": "France", "geoPoint": {"lat": 43.18396, "lon": 3.00141}}, {"facility": "Novo Nordisk Investigational Site", "city": "Roubaix", "zip": "59100", "country": "France", "geoPoint": {"lat": 50.69421, "lon": 3.17456}}, {"facility": "Novo Nordisk Investigational Site", "city": "Budapest", "zip": "1083", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Novo Nordisk Investigational Site", "city": "Budapest", "zip": "1125", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Novo Nordisk Investigational Site", "city": "Budapest", "zip": "H-1212", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Novo Nordisk Investigational Site", "city": "Eger", "zip": "3300", "country": "Hungary", "geoPoint": {"lat": 47.90265, "lon": 20.37329}}, {"facility": "Novo Nordisk Investigational Site", "city": "P\u00e9cs", "zip": "7623", "country": "Hungary", "geoPoint": {"lat": 46.08333, "lon": 18.23333}}, {"facility": "Novo Nordisk Investigational Site", "city": "Daegu", "zip": "705-717", "country": "Korea, Republic of", "geoPoint": {"lat": 35.87028, "lon": 128.59111}}, {"facility": "Novo Nordisk Investigational Site", "city": "Incheon", "zip": "400-103", "country": "Korea, Republic of", "geoPoint": {"lat": 37.45646, "lon": 126.70515}}, {"facility": "Novo Nordisk Investigational Site", "city": "Seoul", "zip": "135-239", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Novo Nordisk Investigational Site", "city": "Bratislava", "zip": "831 01", "country": "Slovakia", "geoPoint": {"lat": 48.14816, "lon": 17.10674}}, {"facility": "Novo Nordisk Investigational Site", "city": "Bratislava", "zip": "851 01", "country": "Slovakia", "geoPoint": {"lat": 48.14816, "lon": 17.10674}}, {"facility": "Novo Nordisk Investigational Site", "city": "Kosice", "zip": "040 01", "country": "Slovakia", "geoPoint": {"lat": 48.71395, "lon": 21.25808}}, {"facility": "Novo Nordisk Investigational Site", "city": "Lucenec", "zip": "98401", "country": "Slovakia", "geoPoint": {"lat": 48.33249, "lon": 19.66708}}, {"facility": "Novo Nordisk Investigational Site", "city": "Presov", "zip": "080 01", "country": "Slovakia", "geoPoint": {"lat": 48.99839, "lon": 21.23393}}, {"facility": "Novo Nordisk Investigational Site", "city": "Zilina", "zip": "01001", "country": "Slovakia", "geoPoint": {"lat": 49.22315, "lon": 18.73941}}, {"facility": "Novo Nordisk Investigational Site", "city": "Ankara", "zip": "06100", "country": "Turkey", "geoPoint": {"lat": 39.91987, "lon": 32.85427}}, {"facility": "Novo Nordisk Investigational Site", "city": "Istanbul", "zip": "34098", "country": "Turkey", "geoPoint": {"lat": 41.01384, "lon": 28.94966}}, {"facility": "Novo Nordisk Investigational Site", "city": "Istanbul", "zip": "34390", "country": "Turkey", "geoPoint": {"lat": 41.01384, "lon": 28.94966}}, {"facility": "Novo Nordisk Investigational Site", "city": "Kocaeli", "zip": "41380", "country": "Turkey", "geoPoint": {"lat": 39.62497, "lon": 27.51145}}]}, "referencesModule": {"references": [{"pmid": "21205123", "type": "RESULT", "citation": "Hollander P, Raslova K, Skjoth TV, Rastam J, Liutkus JF. Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial. Diabetes Obes Metab. 2011 Mar;13(3):268-75. doi: 10.1111/j.1463-1326.2010.01351.x."}], "seeAlsoLinks": [{"label": "Clinical Trials at Novo Nordisk", "url": "http://novonordisk-trials.com"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Between screening and randomisation, eligible subjects were to continue their usual pre-trial oral anti-diabetic drug (OAD) dose and dosing frequency. Subjects on sulphonylurea (SU) treatment randomised to the insulin detemir group had their SU discontinued", "recruitmentDetails": "48 sites in 8 countries: Canada, Finland, France, Hungary, Slovakia, Republic of Korea, Turkey, and the United States of America (USA)", "groups": [{"id": "FG000", "title": "Comb", "description": "Combination therapy of insulin detemir once daily plus sitagliptin added to subject's own pre-trial metformin treatment"}, {"id": "FG001", "title": "Sita", "description": "Monotherapy of sitagliptin once daily added to subject's own pre-trial metformin and/or sulphonylurea (SU) treatment"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "111"}, {"groupId": "FG001", "numSubjects": "111"}]}, {"type": "Exposed", "achievements": [{"groupId": "FG000", "comment": "2 withdrew informed consent. 1 randomised by mistake. 1 non-compliance", "numSubjects": "107"}, {"groupId": "FG001", "comment": "1 non-compliance", "numSubjects": "110"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "97"}, {"groupId": "FG001", "numSubjects": "92"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "14"}, {"groupId": "FG001", "numSubjects": "19"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "5"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Withdrawal Criteria", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Unclassified", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "3"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Comb", "description": "Combination therapy of insulin detemir once daily plus sitagliptin added to subject's own pre-trial metformin treatment"}, {"id": "BG001", "title": "Sita", "description": "Monotherapy of sitagliptin once daily added to subject's own pre-trial metformin and/or sulphonylurea (SU) treatment"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "107"}, {"groupId": "BG001", "value": "110"}, {"groupId": "BG002", "value": "217"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "56.70", "spread": "9.96"}, {"groupId": "BG001", "value": "57.10", "spread": "8.41"}, {"groupId": "BG002", "value": "56.90", "spread": "9.19"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "39"}, {"groupId": "BG001", "value": "60"}, {"groupId": "BG002", "value": "99"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "68"}, {"groupId": "BG001", "value": "50"}, {"groupId": "BG002", "value": "118"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "6"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "96"}, {"groupId": "BG001", "value": "101"}, {"groupId": "BG002", "value": "197"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "14"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "30"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "5"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "83"}, {"groupId": "BG001", "value": "84"}, {"groupId": "BG002", "value": "167"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "15"}]}]}]}, {"title": "HbA1c", "description": "HbA1c = glycosylated haemoglobin A1c", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percent (%) glycosylated haemoglobin", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.52", "spread": "0.65"}, {"groupId": "BG001", "value": "8.52", "spread": "0.65"}, {"groupId": "BG002", "value": "8.52", "spread": "0.65"}]}]}]}, {"title": "Height", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "meters", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1.71", "spread": "0.10"}, {"groupId": "BG001", "value": "1.66", "spread": "0.09"}, {"groupId": "BG002", "value": "1.68", "spread": "0.10"}]}]}]}, {"title": "Body Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "93.1", "spread": "20.2"}, {"groupId": "BG001", "value": "88.2", "spread": "19.2"}, {"groupId": "BG002", "value": "90.6", "spread": "19.8"}]}]}]}, {"title": "BMI", "description": "BMI = Body Mass Index", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "31.79", "spread": "5.20"}, {"groupId": "BG001", "value": "31.90", "spread": "5.91"}, {"groupId": "BG002", "value": "31.85", "spread": "5.56"}]}]}]}, {"title": "Stratification", "description": "Previous OAD treatment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Previous Metformin + Other OAD therapy", "categories": [{"measurements": [{"groupId": "BG000", "value": "83"}, {"groupId": "BG001", "value": "86"}, {"groupId": "BG002", "value": "169"}]}]}, {"title": "Previous Metformin Monotherapy", "categories": [{"measurements": [{"groupId": "BG000", "value": "24"}, {"groupId": "BG001", "value": "24"}, {"groupId": "BG002", "value": "48"}]}]}]}, {"title": "FPG", "description": "FPG = Fasting Plasma Glucose", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "9.69", "spread": "2.23"}, {"groupId": "BG001", "value": "9.79", "spread": "2.36"}, {"groupId": "BG002", "value": "9.74", "spread": "2.29"}]}]}]}, {"title": "Diabetes History", "description": "No. of years subject has been diagnosed with diabetes", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "9.58", "spread": "5.62"}, {"groupId": "BG001", "value": "9.90", "spread": "5.65"}, {"groupId": "BG002", "value": "9.74", "spread": "5.63"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "HbA1c (Glycosylated Haemoglobin A1c)", "populationDescription": "Sample size calculation: Assuming a standard deviation of 1.0 for HbA1c, 100 subjects in each treatment arm would be required to obtain a power of 80% for detecting a HbA1c difference of 0.4%. FAS (Full Analysis Set) is all randomised subjects exposed to at least one dose of trial product with a post baseline observation.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percent (%) glycosylated haemoglobin", "timeFrame": "Week 26", "groups": [{"id": "OG000", "title": "Comb", "description": "Combination therapy of insulin detemir once daily plus sitagliptin added to subject's own pre-trial metformin treatment"}, {"id": "OG001", "title": "Sita", "description": "Monotherapy of sitagliptin once daily added to subject's own pre-trial metformin and/or sulphonylurea (SU) treatment"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "103"}, {"groupId": "OG001", "value": "106"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.08", "spread": "0.09"}, {"groupId": "OG001", "value": "7.64", "spread": "0.09"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis: Difference between mean HbA1c in the two treatment arms is equal to zero. Power calculation: Assuming a standard deviation of 1.0 for HbA1c, 100 subjects in each treatment arm would be required to obtain a power of 80% for detecting a HbA1c difference of 0.4%", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0010", "pValueComment": "No corrections to adjust for multiplicity were performed. Statistical significance threshold was p\\<0.05.", "statisticalMethod": "ANCOVA", "statisticalComment": "Analysis of covariance (ANCOVA) was used; baseline HbA1c was included as covariate and treatment, stratification and country was included as factors", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.55", "ciPctValue": "95", "ciLowerLimit": "-0.77", "ciUpperLimit": "-0.33"}]}, {"type": "SECONDARY", "title": "Number of Subjects Achieving HbA1c Less Than or Equal to 7.0%", "populationDescription": "FAS (Full Analysis Set) is all randomised subjects exposed to at least one dose of trial product with a post baseline observation.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Subjects", "timeFrame": "Week 26", "groups": [{"id": "OG000", "title": "Comb", "description": "Combination therapy of insulin detemir once daily plus sitagliptin added to subject's own pre-trial metformin treatment"}, {"id": "OG001", "title": "Sita", "description": "Monotherapy of sitagliptin once daily added to subject's own pre-trial metformin and/or sulphonylurea (SU) treatment"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "103"}, {"groupId": "OG001", "value": "106"}]}], "classes": [{"title": "Target achieved", "categories": [{"measurements": [{"groupId": "OG000", "value": "46"}, {"groupId": "OG001", "value": "25"}]}]}, {"title": "Target not achieved", "categories": [{"measurements": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "81"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis: Odds ratio is equal to one.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0010", "pValueComment": "No corrections to adjust for multiplicity were performed. Statistical significance threshold was p\\<0.05.", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Treatment group comparison using logistic regression model incl.treatment,stratification factor, country as fixed effects, baseline HbA1c as covariate", "paramType": "Odds Ratio (OR)", "paramValue": "3.20", "ciPctValue": "95", "ciLowerLimit": "1.65", "ciUpperLimit": "6.19"}]}, {"type": "SECONDARY", "title": "Number of Subjects Achieving HbA1c Less Than or Equal to 7.0% Without Symptomatic Hypoglycaemia", "description": "Symptomatic hypoglycaemia is biochemically confirmed hypoglycaemia or major hypoglycaemia", "populationDescription": "FAS (Full Analysis Set) is all randomised subjects exposed to at least one dose of trial product with a post baseline observation.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Subjects", "timeFrame": "Week 26", "groups": [{"id": "OG000", "title": "Comb", "description": "Combination therapy of insulin detemir once daily plus sitagliptin added to subject's own pre-trial metformin treatment"}, {"id": "OG001", "title": "Sita", "description": "Monotherapy of sitagliptin once daily added to subject's own pre-trial metformin and/or sulphonylurea (SU) treatment"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "103"}, {"groupId": "OG001", "value": "106"}]}], "classes": [{"title": "Target achieved", "categories": [{"measurements": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "21"}]}]}, {"title": "Target not achieved", "categories": [{"measurements": [{"groupId": "OG000", "value": "66"}, {"groupId": "OG001", "value": "85"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis: Odds ratio is equal to one.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0080", "pValueComment": "No corrections to adjust for multiplicity were performed. Statistical significance threshold was p\\<0.05.", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Treatment group comparison using logistic regression model incl.treatment,stratification factor, country as fixed effects, baseline HbA1c as covariate", "paramType": "Odds Ratio (OR)", "paramValue": "2.47", "ciPctValue": "95", "ciLowerLimit": "1.26", "ciUpperLimit": "4.81"}]}, {"type": "SECONDARY", "title": "Number of Subjects Achieving HbA1c Less Than or Equal to 6.5%", "populationDescription": "FAS (Full Analysis Set) is all randomised subjects exposed to at least one dose of trial product with a post baseline observation.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Subjects", "timeFrame": "Week 26", "groups": [{"id": "OG000", "title": "Comb", "description": "Combination therapy of insulin detemir once daily plus sitagliptin added to subject's own pre-trial metformin treatment"}, {"id": "OG001", "title": "Sita", "description": "Monotherapy of sitagliptin once daily added to subject's own pre-trial metformin and/or sulphonylurea (SU) treatment"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "103"}, {"groupId": "OG001", "value": "106"}]}], "classes": [{"title": "Target achieved", "categories": [{"measurements": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "11"}]}]}, {"title": "Target not achieved", "categories": [{"measurements": [{"groupId": "OG000", "value": "83"}, {"groupId": "OG001", "value": "95"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis: Odds ratio is equal to one.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.063", "pValueComment": "No corrections to adjust for multiplicity were performed. Statistical significance threshold was p\\<0.05.", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Treatment group comparison using logistic regression model incl.treatment,stratification factor, country as fixed effects, baseline HbA1c as covariate", "paramType": "Odds Ratio (OR)", "paramValue": "2.23", "ciPctValue": "95", "ciLowerLimit": "0.96", "ciUpperLimit": "5.20"}]}, {"type": "SECONDARY", "title": "Number of Subjects Achieving HbA1c Less Than or Equal to 6.5% Without Symptomatic Hypoglycaemia", "description": "Symptomatic hypoglycaemia is biochemically confirmed hypoglycaemia or major hypoglycaemia", "populationDescription": "FAS (Full Analysis Set) is all randomised subjects exposed to at least one dose of trial product with a post baseline observation.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Subjects", "timeFrame": "Week 26", "groups": [{"id": "OG000", "title": "Comb", "description": "Combination therapy of insulin detemir once daily plus sitagliptin added to subject's own pre-trial metformin treatment"}, {"id": "OG001", "title": "Sita", "description": "Monotherapy of sitagliptin once daily added to subject's own pre-trial metformin and/or sulphonylurea (SU) treatment"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "103"}, {"groupId": "OG001", "value": "106"}]}], "classes": [{"title": "Target achieved", "categories": [{"measurements": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "8"}]}]}, {"title": "Target not achieved", "categories": [{"measurements": [{"groupId": "OG000", "value": "88"}, {"groupId": "OG001", "value": "98"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis: Odds ratio is equal to one.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.135", "pValueComment": "No corrections to adjust for multiplicity were performed. Statistical significance threshold was p\\<0.05.", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "2.07", "ciPctValue": "95", "ciLowerLimit": "0.8", "ciUpperLimit": "5.37", "estimateComment": "Treatment group comparison using logistic regression model incl.treatment,stratification factor, country as fixed effects, baseline HbA1c as covariate"}]}, {"type": "SECONDARY", "title": "Change in BMI (Body Mass Index)", "populationDescription": "FAS (Full Analysis Set) is all randomised subjects exposed to at least one dose of trial product with a post baseline observation.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "kg/m^2", "timeFrame": "Week 0, Week 26", "groups": [{"id": "OG000", "title": "Comb", "description": "Combination therapy of insulin detemir once daily plus sitagliptin added to subject's own pre-trial metformin treatment"}, {"id": "OG001", "title": "Sita", "description": "Monotherapy of sitagliptin once daily added to subject's own pre-trial metformin and/or sulphonylurea (SU) treatment"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "103"}, {"groupId": "OG001", "value": "107"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.30", "spread": "0.15"}, {"groupId": "OG001", "value": "-0.58", "spread": "0.14"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.121", "pValueComment": "No corrections to adjust for multiplicity were performed. Statistical significance threshold was p\\<0.05.", "statisticalMethod": "ANCOVA", "statisticalComment": "An analysis of covariance (ANCOVA) was used; baseline was included as covariate and treatment, stratification and country was included as factors.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.28", "ciPctValue": "95", "ciLowerLimit": "-0.07", "ciUpperLimit": "0.63"}]}, {"type": "SECONDARY", "title": "Change in Body Weight", "populationDescription": "FAS (Full Analysis Set) is all randomised subjects exposed to at least one dose of trial product with a post baseline observation.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "kg", "timeFrame": "Week 0, Week 26", "groups": [{"id": "OG000", "title": "Comb", "description": "Combination therapy of insulin detemir once daily plus sitagliptin added to subject's own pre-trial metformin treatment"}, {"id": "OG001", "title": "Sita", "description": "Monotherapy of sitagliptin once daily added to subject's own pre-trial metformin and/or sulphonylurea (SU) treatment"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "103"}, {"groupId": "OG001", "value": "107"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.81", "spread": "0.44"}, {"groupId": "OG001", "value": "-1.66", "spread": "0.42"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.109", "pValueComment": "No corrections to adjust for multiplicity were performed. Statistical significance threshold was p\\<0.05.", "statisticalMethod": "ANCOVA", "statisticalComment": "An analysis of covariance (ANCOVA) was used; baseline was included as covariate and treatment, stratification and country was included as factors.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.84", "ciPctValue": "95", "ciLowerLimit": "-0.19", "ciUpperLimit": "1.88"}]}, {"type": "SECONDARY", "title": "FPG (Fasting Plasma Glucose)", "populationDescription": "FAS (Full Analysis Set) is all randomised subjects exposed to at least one dose of trial product with a post baseline observation.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Week 26", "groups": [{"id": "OG000", "title": "Comb", "description": "Combination therapy of insulin detemir once daily plus sitagliptin added to subject's own pre-trial metformin treatment"}, {"id": "OG001", "title": "Sita", "description": "Monotherapy of sitagliptin once daily added to subject's own pre-trial metformin and/or sulphonylurea (SU) treatment"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "103"}, {"groupId": "OG001", "value": "106"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "6.08", "spread": "0.24"}, {"groupId": "OG001", "value": "8.52", "spread": "0.23"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0010", "pValueComment": "No corrections to adjust for multiplicity were performed. Statistical significance threshold was p\\<0.05.", "statisticalMethod": "ANCOVA", "statisticalComment": "An analysis of covariance (ANCOVA) was used; baseline was included as covariate and treatment, stratification and country was included as factors.", "paramType": "Mean Difference (Final Values)", "paramValue": "-2.45", "ciPctValue": "95", "ciLowerLimit": "-3.01", "ciUpperLimit": "-1.88"}]}, {"type": "SECONDARY", "title": "Hypoglycemic Episodes", "description": "Overall: All episodes. Minor: Symptomatic, with PG \\< 3.1 mmol/L. Symptoms only: Symptomatic with PG \u2265 3.1 mmol/L", "populationDescription": "SAS (safety analysis set) is all randomised subjects exposed to at least one dose of trial product.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "episodes", "timeFrame": "Weeks 0-26", "groups": [{"id": "OG000", "title": "Comb", "description": "Combination therapy of insulin detemir once daily plus sitagliptin added to subject's own pre-trial metformin treatment"}, {"id": "OG001", "title": "Sita", "description": "Monotherapy of sitagliptin once daily added to subject's own pre-trial metformin and/or sulphonylurea (SU) treatment"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "110"}]}], "classes": [{"title": "Overall", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Minor", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Symptoms Only", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Unclassified", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Hypoglycemic Episodes: Day Time", "description": "Day time: Episodes between 6 pm and 11 am. Overall: All episodes. Minor: Symptomatic, with PG \\< 3.1 mmol/L. Symptoms only: Symptomatic with PG \u2265 3.1 mmol/L", "populationDescription": "SAS (safety analysis set) is all randomised subjects exposed to at least one dose of trial product.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "episodes", "timeFrame": "Weeks 0-26", "groups": [{"id": "OG000", "title": "Comb", "description": "Combination therapy of insulin detemir once daily plus sitagliptin added to subject's own pre-trial metformin treatment"}, {"id": "OG001", "title": "Sita", "description": "Monotherapy of sitagliptin once daily added to subject's own pre-trial metformin and/or sulphonylurea (SU) treatment"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "110"}]}], "classes": [{"title": "Overall", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Minor", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Symptoms Only", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Unclassified", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Hypoglycemic Episodes: Night Time", "description": "Night time: Episodes between 11 am and 6 pm. Overall: All episodes. Minor: Symptomatic, with PG \\< 3.1 mmol/L. Symptoms only: Symptomatic with PG \u2265 3.1 mmol/L", "populationDescription": "SAS (safety analysis set) is all randomised subjects exposed to at least one dose of trial product.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "episodes", "timeFrame": "Weeks 0-26", "groups": [{"id": "OG000", "title": "Comb", "description": "Combination therapy of insulin detemir once daily plus sitagliptin added to subject's own pre-trial metformin treatment"}, {"id": "OG001", "title": "Sita", "description": "Monotherapy of sitagliptin once daily added to subject's own pre-trial metformin and/or sulphonylurea (SU) treatment"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "110"}]}], "classes": [{"title": "Overall", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Minor", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Symptoms Only", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Unclassified", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Self-measured 9-point Plasma Glucose Profile", "populationDescription": "FAS (Full Analysis Set) is all randomised subjects exposed to at least one dose of trial product with a post baseline observation.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Week 26", "groups": [{"id": "OG000", "title": "Comb", "description": "Combination therapy of insulin detemir once daily plus sitagliptin added to subject's own pre-trial metformin treatment"}, {"id": "OG001", "title": "Sita", "description": "Monotherapy of sitagliptin once daily added to subject's own pre-trial metformin and/or sulphonylurea (SU) treatment"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "98"}, {"groupId": "OG001", "value": "98"}]}], "classes": [{"title": "Before breakfast", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.16", "spread": "0.20"}, {"groupId": "OG001", "value": "8.17", "spread": "0.20"}]}]}, {"title": "120 minutes after start of breakfast", "categories": [{"measurements": [{"groupId": "OG000", "value": "8.82", "spread": "0.28"}, {"groupId": "OG001", "value": "10.50", "spread": "0.28"}]}]}, {"title": "Before Lunch", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.99", "spread": "0.26"}, {"groupId": "OG001", "value": "8.01", "spread": "0.26"}]}]}, {"title": "120 minutes after start of lunch", "categories": [{"measurements": [{"groupId": "OG000", "value": "8.69", "spread": "0.28"}, {"groupId": "OG001", "value": "9.99", "spread": "0.28"}]}]}, {"title": "Before dinner", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.85", "spread": "0.31"}, {"groupId": "OG001", "value": "8.61", "spread": "0.31"}]}]}, {"title": "120 minutes after start of dinner", "categories": [{"measurements": [{"groupId": "OG000", "value": "9.30", "spread": "0.32"}, {"groupId": "OG001", "value": "10.20", "spread": "0.32"}]}]}, {"title": "Bedtime", "categories": [{"measurements": [{"groupId": "OG000", "value": "8.38", "spread": "0.32"}, {"groupId": "OG001", "value": "9.42", "spread": "0.31"}]}]}, {"title": "At 03:00 A.M.", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.85", "spread": "0.26"}, {"groupId": "OG001", "value": "8.02", "spread": "0.26"}]}]}, {"title": "Before breakfast the following day", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.07", "spread": "0.19"}, {"groupId": "OG001", "value": "7.87", "spread": "0.19"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "Linear Mixed-model", "statisticalComment": "PG profile analysis:linear mixed effect model.Treatment,time,country,time-by-treatment interaction as explanatory variables.Subject as a random factor", "paramType": "Mean Difference (Final Values)", "paramValue": "-2.01", "ciPctValue": "95", "ciLowerLimit": "-2.50", "ciUpperLimit": "-1.51", "estimateComment": "COMB-SITA Difference. Before breakfast"}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "Linear Mixed-model", "statisticalComment": "PG profile analysis:linear mixed effect model.Treatment,time,country,time-by-treatment interaction as explanatory variables.Subject as a random factor", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.64", "ciPctValue": "95", "ciLowerLimit": "-2.40", "ciUpperLimit": "-0.89", "estimateComment": "COMB-SITA Difference. 120 minutes after start of breakfast"}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "Linear Mixed-model", "statisticalComment": "PG profile analysis:linear mixed effect model.Treatment,time,country,time-by-treatment interaction as explanatory variables.Subject as a random factor", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.02", "ciPctValue": "95", "ciLowerLimit": "-1.69", "ciUpperLimit": "-0.35", "estimateComment": "COMB-SITA Difference. Before lunch"}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "Linear mixed-model", "statisticalComment": "PG profile analysis:linear mixed effect model.Treatment,time,country,time-by-treatment interaction as explanatory variables.Subject as a random factor", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.30", "ciPctValue": "95", "ciLowerLimit": "-2.05", "ciUpperLimit": "-0.56", "estimateComment": "COMB-SITA Difference. 120 minutes after start of lunch"}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "Linear Mixed-model", "statisticalComment": "PG profile analysis:linear mixed effect model.Treatment,time,country,time-by-treatment interaction as explanatory variables.Subject as a random factor", "paramType": "Median Difference (Final Values)", "paramValue": "-0.77", "ciPctValue": "95", "ciLowerLimit": "-1.58", "ciUpperLimit": "0.05", "estimateComment": "COMB-SITA Difference. Before dinner"}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "Linear Mixed-model", "statisticalComment": "PG profile analysis:linear mixed effect model.Treatment,time,country,time-by-treatment interaction as explanatory variables.Subject as a random factor", "paramType": "Median Difference (Final Values)", "paramValue": "-0.88", "ciPctValue": "95", "ciLowerLimit": "-1.75", "ciUpperLimit": "-0.02", "estimateComment": "COMB-SITA Difference. 120 minutes after start of dinner"}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "Linear Mixed-model", "statisticalComment": "PG profile analysis:linear mixed effect model.Treatment,time,country,time-by-treatment interaction as explanatory variables.Subject as a random factor", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.04", "ciPctValue": "95", "ciLowerLimit": "-1.88", "ciUpperLimit": "-0.20", "estimateComment": "COMB-SITA Difference. Bedtime"}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "Linear Mixed Model", "statisticalComment": "PG profile analysis:linear mixed effect model.Treatment,time,country,time-by-treatment interaction as explanatory variables.Subject as a random factor", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.17", "ciPctValue": "95", "ciLowerLimit": "-1.84", "ciUpperLimit": "-0.49", "estimateComment": "COMB-SITA Difference. At 03:00 a.m."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "Linear Mixed-model", "statisticalComment": "PG profile analysis:linear mixed effect model.Treatment,time,country,time-by-treatment interaction as explanatory variables.Subject as a random factor", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.80", "ciPctValue": "95", "ciLowerLimit": "-2.26", "ciUpperLimit": "-1.34", "estimateComment": "COMB-SITA Difference. Before breakfast the following day"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Weeks 0-26", "description": "Safety Analysis Set is all participants treated with trial product.", "eventGroups": [{"id": "EG000", "title": "Comb", "description": "Combination therapy of insulin detemir once daily plus sitagliptin added to subject's own pre-trial metformin treatment", "seriousNumAffected": 2, "seriousNumAtRisk": 107, "otherNumAffected": 76, "otherNumAtRisk": 107}, {"id": "EG001", "title": "Sita", "description": "Monotherapy of sitagliptin once daily added to subject's own pre-trial metformin and/or sulphonylurea (SU) treatment", "seriousNumAffected": 4, "seriousNumAtRisk": 110, "otherNumAffected": 72, "otherNumAtRisk": 110}], "seriousEvents": [{"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 107}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 110}]}, {"term": "Optic ischaemic neuropathy", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 107}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 110}]}, {"term": "Bile duct obstruction", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 107}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 110}]}, {"term": "Bronchopneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 107}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 110}]}, {"term": "Fibromatosis", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 107}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 110}]}, {"term": "Alcohol withdrawal syndrome", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 107}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 110}]}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 13, "numAffected": 10, "numAtRisk": 76}, {"groupId": "EG001", "numEvents": 16, "numAffected": 14, "numAtRisk": 72}]}, {"term": "Upper Respiratory Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 7, "numAtRisk": 76}, {"groupId": "EG001", "numEvents": 12, "numAffected": 10, "numAtRisk": 72}]}, {"term": "Influenza", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 9, "numAffected": 8, "numAtRisk": 76}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 72}]}, {"term": "Bronchitis", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 76}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 72}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 5, "numAtRisk": 76}, {"groupId": "EG001", "numEvents": 20, "numAffected": 8, "numAtRisk": 72}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 5, "numAtRisk": 76}, {"groupId": "EG001", "numEvents": 11, "numAffected": 3, "numAtRisk": 72}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 17, "numAffected": 11, "numAtRisk": 76}, {"groupId": "EG001", "numEvents": 32, "numAffected": 13, "numAtRisk": 72}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 76}, {"groupId": "EG001", "numEvents": 21, "numAffected": 4, "numAtRisk": 72}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 76}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 72}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 9, "numAffected": 8, "numAtRisk": 76}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 72}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 76}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 72}]}, {"term": "Myalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 76}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 72}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 7, "numAtRisk": 76}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 72}]}, {"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 76}, {"groupId": "EG001", "numEvents": 12, "numAffected": 5, "numAtRisk": 72}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 76}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 72}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 76}, {"groupId": "EG001", "numEvents": 12, "numAffected": 11, "numAtRisk": 72}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Novo Nordisk reserves the right not to release data before passing specified milestones. This includes the right not to release interim results that may later be found to be incorrect. At the end of the trial, one or more manuscripts will be prepared in collaboration between Investigator(s) and Novo Nordisk. Novo Nordisk will not suppress or veto publications but will reserve the right to postpone publication and/or communication for a short time to protect intellectual property."}, "pointOfContact": {"title": "Public Access to Clinical Trials", "organization": "Novo Nordisk A/S", "email": "clinicaltrials@novonordisk.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Type 2", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000068900", "term": "Sitagliptin Phosphate"}, {"id": "D000069057", "term": "Insulin Detemir"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M10365", "name": "Insulin", "relevance": "LOW"}, {"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M173166", "name": "Insulin, Globin Zinc", "relevance": "LOW"}, {"id": "M349", "name": "Insulin Detemir", "asFound": "Oocyte", "relevance": "HIGH"}, {"id": "M335", "name": "Sitagliptin Phosphate", "asFound": "Percutaneous", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}